EYPT vs. LAB, CTKB, QTRX, PACB, NAUT, HBIO, BNGO, AXDX, OLK, and TXG
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include Standard BioTools (LAB), Cytek Biosciences (CTKB), Quanterix (QTRX), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Olink Holding AB (publ) (OLK), and 10x Genomics (TXG).
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
In the previous week, EyePoint Pharmaceuticals had 6 more articles in the media than Standard BioTools. MarketBeat recorded 9 mentions for EyePoint Pharmaceuticals and 3 mentions for Standard BioTools. EyePoint Pharmaceuticals' average media sentiment score of 0.91 beat Standard BioTools' score of 0.50 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.
EyePoint Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
EyePoint Pharmaceuticals received 444 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 69.73% of users gave EyePoint Pharmaceuticals an outperform vote.
Standard BioTools has a net margin of -70.21% compared to EyePoint Pharmaceuticals' net margin of -153.84%. Standard BioTools' return on equity of 0.00% beat EyePoint Pharmaceuticals' return on equity.
EyePoint Pharmaceuticals has higher earnings, but lower revenue than Standard BioTools. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are owned by company insiders. Comparatively, 53.1% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
EyePoint Pharmaceuticals currently has a consensus target price of $34.00, indicating a potential upside of 85.49%. Standard BioTools has a consensus target price of $3.58, indicating a potential upside of 38.89%. Given EyePoint Pharmaceuticals' higher possible upside, equities analysts plainly believe EyePoint Pharmaceuticals is more favorable than Standard BioTools.
Summary
EyePoint Pharmaceuticals and Standard BioTools tied by winning 8 of the 16 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
